scholarly journals Comparative study on the efficacy and safety of pilsicainide with disopyramide on paroxysmal atrial fibrillation, paroxysmal atrial flutter and paroxysmal atrial tachycardia. Open randomized multicenter study.

1999 ◽  
Vol 19 (4) ◽  
pp. 332-343
Author(s):  
Nobuo Ikeda ◽  
Junji Toyama ◽  
Kazuo Yamada ◽  
Mitsuhiro Yokota ◽  
Rinya Katoh ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Comparative Study ◽  
Atrial Flutter ◽  
Multicenter Study ◽  
Paroxysmal Atrial Fibrillation ◽  
Atrial Tachycardia ◽  
Efficacy And Safety

scholarly journals Six-months success of radiofrequency ablation in cardiac arrhythmias treatment: Experience of our centre

2019 ◽  
Vol 76 (4) ◽  
pp. 398-403
Author(s):  
Ruzica Jurcevic-Mudric ◽  
Lazar Angelkov ◽  
Milosav Tomovic ◽  
Dejan Kojic ◽  
Predrag Milojevic
Keyword(s):  
Atrial Fibrillation ◽  
Ventricular Tachycardia ◽  
Radiofrequency Ablation ◽  
Atrial Flutter ◽  
Cardiac Arrhythmias ◽  
Paroxysmal Atrial Fibrillation ◽  
Atrial Tachycardia ◽  
Pulmonary Veins ◽  
Av Node

Background/Aim. Numerous trials have shown a high success of radiofrequency ablation (RFA) in the treatment of the patients with cardiac arrhythmias. We aimed to examine the RFA initial success in treatment of different cardiac arrhythmias and the RFA success after 6 months of followup. Second aim was to evaluate influence of all clinical and echocardiography parameters on initial and 6-month success and failure of RFA. Methods. The present study included 320 consecutive patients with atrial and ventricular arrhythmias in which RFA was performed during 2014 in the Institute for Cardiovascular Diseases ?Dedinje?, Belgrade, Serbia. We evaluated the initial RFA success and success of this procedure after 6-month follow-up. We also investigated the prognostic role of clinical and echocardiography parameters on initial and 6-month success and failure of RFA. Results. The RFA initial success for RFA of atrioventriculas (AV) node and AV nodal reentrant tachycardia (AVNRT) was 100%, RFA of pulmonary veins 99%, RFA of atrial flutter 92%, RFA of premature ventricular complexes (PVC) and the Wolf-Parkinson-White (WPW) syndrome 87%, RFA of ventricular tachycardia 85% and RFA of atrial tachycardia 78%. The success of RFA after 6 months of follow-up for RFA of the AV node was 100%, RFA of AVNRT 94%, RFA of atrial flutter 90%, RFA of WPW syndrome 86%, RFA of pulmonary veins 79% (paroxysmal atrial fibrillation 88% and persistent atrial fibrillation 63% with a significant difference p < 0.05), RFA of PVC 78%, RFA of ventricular tachycardia 77% and RFA of atrial tachycardia 67%. Conclusion. This study proved a very high RFA initial success in treatment of cardiac arrhythmias and a satisfactory RFA success after 6 months of follow-up. Only the prognostic value had the type of atrial fibrillation in the group with catheter ablated pulmonary veins: after 6-month follow-up, the patients with paroxysmal atrial fibrillation had a significantly better outcome than those with persistent form.

Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter

1992 ◽  
Vol 69 (4) ◽  
pp. 417-419 ◽  
Author(s):  
Maarten J. Suttorp ◽  
Peter E. Polak ◽  
Arnoud van't Hof ◽  
Henrik S. Rasmussen ◽  
Peter H. Dunselman ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Atrial Flutter ◽  
Paroxysmal Atrial Fibrillation ◽  
Antiarrhythmic Agent ◽  
Efficacy And Safety ◽  
Class Iii ◽  
Class Iii Antiarrhythmic Agent

Abstract 15927: Successful Pharmacological Cardioversion by Oral Amiodarone Therapy is Correlated With Favorable Post-Ablation Clinical Outcomes in Non-Paroxysmal Atrial Fibrillation

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Kiyoshi Otomo ◽  
Kaname Takizawa ◽  
Naoto Inoue ◽  
Taiichiro Meguro
Keyword(s):  
Atrial Fibrillation ◽  
Sinus Rhythm ◽  
Atrial Flutter ◽  
Clinical Outcomes ◽  
Paroxysmal Atrial Fibrillation ◽  
Atrial Tachycardia ◽  
Amiodarone Therapy ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Pharmacological Cardioversion

Backgrounds: Catheter ablation (CA) for non-paroxysmal atrial fibrillation (AF)(non-PAF) is less successful in patients (pts) with highly remodeled atria. It is still controversial that how far CA should be indicated in non-PAF pts with highly remodeled atria. Impacts of successful pharmacological cardioversion of non-PAF by oral amiodarone (AMD) on post-CA clinical outcomes remain to be evaluated. Purposes: To assess efficacy of oral AMD and implications of successful cardioversion by AMD in advance to CA on post-CA clinical outcomes in non-PAF pts. Methods: In consecutive 418 non-PAF pts (age: 63±9 years, AF duration: 28±37 months, LA diameter: 44±5mm), oral AMD (300 mg/day for 2 weeks and 100 mg/day thereafter) was initiated at outpatient clinic one month prior to the initial CA procedure. Recurrence-free survival after last CA procedure was compared between those with successful pharmacological conversion to sinus rhythm, atrial flutter or atrial tachycardia by the time of the initial CA procedure (Group non-AF) and those without (Group AF) . Results: At the beginning of initial CA procedure, 79 pts were in sinus rhythm, 8 in typical atrial flutter, 3 in atrial tachycardia (Group non-AF: 90 pts (22%)) and the remaining 328 still in AF (Group AF: 78%) . During follow-up period of 287±204 days after last CA procedure (procedure number:1.6±0.7/pt, range: 1-4), 45 pts (11%) were followed up while taking AMD, whereas the other 373 pts (89%) without any antiarrhythmic drugs. Kaplan-Meier analysis revealed that recurrence-free survival after last CA procedure was significantly higher in Group non-AF than in Group AF (88 (98%) vs. 291 (89%) pts; p=0.02) . Group non-AF pts exhibited significantly shorter AF duration (9±9 (range: 1-46) vs. 33±41 months (range: 1-240): p<0.0001) and smaller LA diameter (42±5 (range: 28-54) vs. 44±5 mm (range: 31-61): p<0.0001) as compared with those in Group AF pts. Conclusions: Successful cardioversion by AMD in advance to CA was correlated with higher recurrence-free survival after last CA procedure. This simple criterion is helpful to find pts with less remodeled atria and good candidates for CA who will benefit from CA in non-PAF pts.

The efficacy and safety of cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation

2021 ◽  
Author(s):  
Adil K. Baimbetov ◽  
Kuat B. Abzaliev ◽  
Aiman M. Jukenova ◽  
Kenzhebek A. Bizhanov ◽  
Binali A. Bairamov ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Catheter Ablation ◽  
Paroxysmal Atrial Fibrillation ◽  
Efficacy And Safety

scholarly journals Clinical Efficacy of Bepridil for Class I Antiarrhythmic Drug-Induced Atrial Flutter in Patients with Paroxysmal Atrial Fibrillation

2008 ◽  
Vol 24 (2) ◽  
pp. 71-75
Author(s):  
Hidemori Hayashi ◽  
Masataka Sumiyoshi ◽  
Satoru Suwa ◽  
Hidehiko Sakurai ◽  
Yasunobu Kawano ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Atrial Flutter ◽  
Clinical Efficacy ◽  
Antiarrhythmic Drug ◽  
Paroxysmal Atrial Fibrillation ◽  
Class I ◽  
Drug Induced ◽  
Class I Antiarrhythmic Drug

scholarly journals MEDICATION FOR PHARMACOLOGICAL CARDIOVERSION OF PAROXYSMAL ATRIAL FIBRILLATION AT THE PREHOSPITAL STAGE: STUDY OF EFFICACY AND SAFETY

2018 ◽  
Vol 18 (4) ◽  
pp. 43-47
Author(s):  
I. Y. Lukianova ◽  
A. V. Kuzneztov ◽  
V. M. Komarnitzkii ◽  
A. G. Kozyreva
Keyword(s):  
Atrial Fibrillation ◽  
Sinus Rhythm ◽  
Paroxysmal Atrial Fibrillation ◽  
Efficacy And Safety ◽  
Pharmacological Cardioversion

This study demonstrates the effectiveness of procainamide, propafenone and amiodaronefor pharmacological cardioversion in patients with paroxysmal atrial fibrillation. The restoration of the sinus rhythm within 60 minutes was observed for propafenone 73,2%, for procainamide 55,00% and for amiodarone 16,13% of cases.

Arrhythmias, conduction disturbances, and neurocardiogenic syncope

2010 ◽  
pp. 113-174
Author(s):  
Juan Carlos Kaski
Keyword(s):  
Atrial Fibrillation ◽  
Atrial Flutter ◽  
Paroxysmal Atrial Fibrillation ◽  
Persistent Atrial Fibrillation ◽  
Acute Onset ◽  
Atrial Arrhythmias ◽  
Neurocardiogenic Syncope ◽  
Conduction Disturbances ◽  
Permanent Atrial Fibrillation ◽  
Onset Atrial Fibrillation

Atrial fibrillation 114 New (acute)-onset atrial fibrillation 116 Paroxysmal atrial fibrillation 118 Persistent atrial fibrillation 120 Permanent atrial fibrillation 122 Secondary atrial fibrillation 124 Drugs used in electrical and chemical cardioversion 126 Antithrombotic treatment 128 Atrial flutter 132 Supraventricular (narrow complex) tachycardias 134 Landmark trials for atrial arrhythmias ...

Sign in / Sign up

Export Citation Format

Share Document